Omadacycline — The Newest Tetracycline
Omadacycline — The Newest Tetracycline
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Omadacycline was the second antibiotic of the tetracycline class to be approved by the Food and Drug Administration (FDA) in 2018. Results of two phase 3, double-blind, randomized clinical trials of the drug, one involving acute bacterial skin and skin-structure infections and the other community-acquired bacterial pneumonia, are now reported in th...
Alternative Titles
Full title
Omadacycline — The Newest Tetracycline
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2229085383
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2229085383
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMe1900188
